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Abstract
Background—Depression affects 20-30% of people with HIV. Randomized controlled trials 
(RCTs) have demonstrated the effectiveness of interventions to improve depression among HIV-
infected adults, but typically have highly selected populations which may limit generalizability. 
Inverse probability of sampling weights (IPSW) are a recently proposed method to transport (or 
standardize) findings from RCTs to a specific external target population.
Methods—We used IPSW to transport the 6-month effect of the Measurement-Based Care 
(MBC) intervention on depression from the SLAM DUNC trial to a population of HIV-infected 
depressed adults in routine care in the United States between 2010 and 2014.
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Results—In the RCT, MBC was associated with an improvement in depression at 6 months of 
3.6 points on the Hamilton Depression Rating scale (95% CI: -5.9, -1.3). When IPSW were used 
to standardize results from the trial to the target population, the intervention effect was attenuated 
by 1.2 points (mean improvement 2.4 points; 95% CI: -6.1, 1.3).
Conclusions—If implemented among HIV-infected depressed adults in routine care, MBC may 
be less effective than in the RCT but can still be expected to reduce depression. Attenuation of the 
intervention effect among adults in routine care reflects the fact that the trial enrolled a larger 
proportion of individuals for whom the intervention was more effective. Given the burden of 
depression among HIV-infected adults, more effective interventions to improve depression are 
urgently needed. However, examining the transportability of trial findings is essential to 
understand whether similar effects can be expected if interventions are scaled-up.
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Introduction
Depression affects 20-30% of people living with HIV (PLWH), making it the most 
commonly reported mental health condition among adults in HIV care in the United 
States.1,2 For PLWH, depression is a debilitating condition that negatively affects quality of 
life,3,4 antiretroviral (ART) adherence5-7 and viral suppression.8-10 Antidepressant 
medications are effective at treating severe depression in HIV-infected adults.11 However, 
identifying and effectively treating PLWH with depression remains a challenge.12 Less than 
20% of HIV-infected persons with depression are estimated to receive any depression 
treatment, and just 9% to receive adequate treatment.13
Randomized controlled trials (RCTs) have demonstrated the efficacy of interventions to 
improve depression among both HIV-infected and uninfected adults.14,15 While RCTs 
typically have strong internal validity, they often have limited external validity.16,17 External 
validity is compromised when the study population enrolled in the RCT does not accurately 
represent the target population for implementation of the intervention and when the 
distribution of effect-measure modifiers between the trial and target populations differ.18 
RCTs evaluating mental health outcomes in particular often have stringent eligibility criteria, 
which may result in under-representation of individuals with complicated or comorbid 
mental health conditions.19-21
A clear understanding of the external validity of RCT results is critical for practitioners and 
policymakers considering scaling-up mental health interventions. However, only recently 
have methods been developed to quantitatively assess the extent to which findings from 
RCTs can be generalized or ‘transported’ to a specific target population.18,22 In the current 
analysis, we report on the use of inverse probability of sampling weights (IPSW)18 to 
transport, or standardize, the effect estimate from a RCT of depression treatment among 
depressed, HIV-infected adults to a target population of HIV-infected depressed adults 
receiving HIV care at multiple clinical sites across the US.
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Methods
The goal of the present analysis was to assess what effect the Measurement-Based Care 
(MBC) intervention might have on depression if implemented among HIV-infected, 
depressed adults in routine care in a multisite observational cohort. IPSW offer a way to 
quantitatively assess what the effect of an intervention tested in a RCT might be if 
implemented in the target population, by taking into account measured differences between 
the study and target populations. The concept of ‘transportability’ is closely related to 
generalizability. However, ‘transportability’ is preferred to distinguish settings in which the 
trial population is not a complete subset of the target population.23
Study population and data sources
Data for the present analysis come from two data sources: 1) the SLAM DUNC trial, which 
evaluated the efficacy of MBC on mental health and HIV outcomes24 and 2) the Centers for 
AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) cohort.
The SLAM DUNC trial has been described in detail elsewhere.24 Briefly, HIV-infected 
persons receiving medical care at one of four US infectious disease clinics (2 of which – 
University of North Carolina, Chapel Hill (UNC) and University of Alabama, Birmingham 
(UAB) - are also CNICS sites) were eligible to participate if they were English speaking, 
ages 18-64, screened positive for depression (score ≥10) on the Patient Health 
Questionnaire-9 (PHQ-9)25, and were confirmed to have a current major depressive disorder 
on the Mini International Neuropsychiatric Interview (MINI) that was not treatment 
resistant.26 Exclusion criteria included history of bipolar or psychotic disorder, failure of> 2 
adequate antidepressant trials in the current depressive episode, or psychiatric presentation 
requiring acute intervention. Participants were randomized to receive either enhanced usual 
care for depression or the MBC intervention.27 The MBC intervention consisted of a 
clinically supervised Depression Care Manager (DCM) who provided evidence-based 
antidepressant treatment recommendations to the HIV provider. DCM recommendations 
focused on initiation of antidepressants and dose adjustment based on algorithm-centered 
depressive symptom response and tolerability; HIV providers made all final decisions about 
treatment. Participants randomized to the enhanced usual care arm could have also received 
depression treatment from their HIV provider or other sources, but no in-clinic decision 
support was provided by the DCM. All participants provided written informed consent, and 
ethical approval was provided by Duke University, UNC and UAB.
The CNICS cohort includes over 30,000 PLWH in routine clinical care at 8 sites in the 
United States.28 CNICS collects detailed information on demographics, ART, antidepressant 
medications, HIV/AIDS clinical events, co-morbid conditions, HIV-related lab values and 
vital status on patients who consent to participate. Between 2005 and 2011, CNICS sites 
began collecting self-administered socio-behavioral questionnaires, called Patient-Reported 
Measures and Outcomes (PROs), approximately every 4-6 months. The PROs include a 
validated measure of depression (PHQ-9). Ethical approval for the use of routinely collected 
clinical data was provided by all CNICS sites.
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Data for the present analysis includes all SLAM DUNC participants (n=304; intervention 
arm n=149, usual care arm n=155). Patients in CNICS were included if they met modified 
SLAM DUNC inclusion criteria, including being age 18-64, having a PHQ-9 ≥10 between 
March 31, 2010 and December 1, 2014 (enrollment period for SLAM DUNC), and no 
bipolar or psychotic disorder history (n=3,176). Baseline for SLAM DUNC participants was 
defined as study enrollment and for CNICS participants as the first visit with a PHQ-9 
measure> 10 in the study period. The outcome of interest was depression severity at 6 
months, measured using the Hamilton Depression Rating Scale (HAM-D).29
Weights estimation
We created two types of weights to address two separate issues. First, we created inverse 
probability of observation weights (IPOW) to address possible selection bias from missing 
HAM-D outcomes (n=119) in the SLAM DUNC trial population only. Second, we created 
IPSW to standardize the effect of the MBC intervention on depression at 6 months among 
trial participants to our target population of HIV-infected, depressed adults in CNICS. We 
explored the bias-variance trade-off of progressively truncating the weights between 
percentiles 0 to 5 and 95 to 100 and chose stabilized weights with a mean as close to 1.00 as 
possible and a reasonable range (Supplemental Digital Content AppendixTable 1).
IPOW were created using data from SLAM DUNC participants only. An indicator variable 
for having an observed versus missing 6-month HAM-D measurement was created and the 
probability of having an observed outcome measure was estimated as a function of a 
participant's baseline adaptive coping30,31, viral load suppression (<50 copies/mL), self-
efficacy,32 self-reported ART adherence, HAM-D score, appointment adherence (0-100%) 
and alcohol use (Table 1). Predictors were identified based on previous investigations of 
predictors of missing information in these data.15 IPOW were stabilized by the marginal 
probability of having an observed outcome and were truncated at the 5th and 95th percentiles 
to improve stability.
To create IPSW to assess transportability, we first considered covariates available in both 
data sources likely to be associated with trial participation and to modify the effect of the 
intervention on depression.18 Not all covariates associated with selection into the trial were 
also effect-measure modifiers (Figure 2 and Figure 3). For parsimony, only the following 
baseline covariates were used to create the IPSW: PHQ9 score, panic disorder, ART use and 
adherence, gender, race/ethnicity, risk group for HIV acquisition, age, CD4 count, viral load 
suppression and years in care (Table 1). After harmonizing variable categorization, the two 
data sources were combined. IPSW were estimated as the inverse odds of inclusion in 
SLUM DUNC, as a function of included covariates. One-way interactions were considered, 
but taken out of the final IPSW model to improve model stability. IPSW were stabilized by 
the marginal odds of selection into SLAM DUNC and truncated at the 1st and 99th 
percentiles.18
Statistical analysis
We conducted an intent-to-treat (ITT) analysis and used linear regression to estimate the 
effect of the MBC intervention on mean HAM-D score at 6 months. All models included 
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fixed effects for design variables (site and physician's depression treatment experience) and 
used robust variance estimators. Standard errors were bootstrapped (n=1,000) to obtain 95% 
confidence intervals (CIs). We compared unweighted and weighted effect estimates.
The weighted analysis proceeded in four steps. First, we performed multiple imputation 
using chained equations33 (n=20 imputations) to fill in missing data for all covariates in both 
SLAM DUNC and CNICS that were used to create the IPOW or IPSW. Second, using 
imputed data from SLAM DUNC participants only, we calculated and applied IPOW to 
reweight those with observed outcomes to represent the entire SLAM DUNC study 
population. Third, using imputed data from SLAM DUNC and CNICS combined, we 
calculated and applied IPSW to standardize effect estimates from SLAM DUNC to our 
target population in CNICS. In the final analysis, we multiplied the IPOW and IPSW 
together to address both missing outcomes and transportability.
We conducted two sensitivity analyses. Due to the low number of persons in certain 
categories in the SLAM DUNC study population (those not on ART at study start, Hispanic/
other ethnicity, and intravenous drug users (IDUs)), we conducted a sensitivity analysis 
excluding these groups from both samples. We also included only CNICS sites from the 
same geographic region as SLAM DUNC study sites (UNC and UAB) in order to 
understand whether changes in transported effects were largely attributable to differences in 
the distribution of the HIV epidemic in the Southeast United States, compared with the rest 
of the US. All analyses were performed using Stata 13 (StataCorp, College Station, TX).
Results
A total of 3,176 patients in CNICS met the modified inclusion criteria for SLAM DUNC and 
were included in the analysis. Of the 304 participants enrolled in SLAM DUNC, n=190 
(63%; intervention arm n=92, usual care n=98) had HAM-D measurements at 6 months 
(Supplemental Digital Content Appendix Table 2). Missing data was a challenge in the 
SLAM DUNC trial; 77% of participants completed at least one follow-up at either 3, 6, 9 or 
12 months but interim missing data were common.15 Extensive investigation of missing data 
for the primary analysis of the trial showed that missingness with respect to both HIV and 
mental health outcomes was balanced by arm. Additionally, methods to correct for missing 
data34 in the analysis of the primary findings from trial did not yield meaningful changes in 
effect estimates.15 In line with these findings, there was little difference between the entire 
SLAM DUNC study population and those with a HAM-D measurement at 6 months among 
previously identified predictors of missing data in our analysis (Figure 1).
Compared with participants in SLAM DUNC, CNICS participants were more likely to have 
panic disorder (30% versus 14%), use drugs (25% versus 18%) and not be on ART at 
baseline (25% versus 6%). SLAM DUNC participants were more likely to be female (29% 
versus 17%), black, non-Hispanic (62% versus 29%), to have contracted HIV through 
heterosexual transmission (40% versus 22%) and to have more severe depression (PHQ-9 
20-27; 23% versus 17%) (Figure 2).
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In the unweighted ITT analysis, MBC was associated with a mean decrease (e.g. 
improvement) of 3.6 points on the HAM-D scale (95% CI: -5.9, -1.3) at 6 months (Table 2). 
When the effect of MBC on HAM-D scores at 6 months was investigated within sub-groups, 
the effect of the intervention was attenuated among those with higher PHQ-9 scores (-1.2; 
95% CI: -7.6, 5.3), white, non-Hispanics (0.9; 95% CI -2.9, 4.7), individuals aged 30-39 
(0.2; 95% CI -6.0, 6.3), those with CD4 count 351-500 (-0.7; 95% CI: -4.8, 3.5) and those in 
care< 1 year (2.9; 95% CI: -3.3, 9.2) (Figure 3). The effect of the intervention was stronger 
among those on ART and not adherent at baseline (-5.0; 95% CI: -9.4, -0.6), black, non-
Hispanics (-5.1; 95% CI: -8.5, -1.7), Hispanic or other race/ethnicity (-5.3; 95% CI: -11.5, 
0.9), those who acquired HIV through IDU (-13.5; 95% CI: -28.4, 1.4) and individuals in 
care >10 years (-8.0; 95% CI: -12.2, -3.7) (Figure 3).
In the weighted analysis, when only IPOW were used the intervention effect was similar to 
the unweighted ITT analysis (mean decrease -3.6; 95% CI: -6.0, -1.3), suggesting that 
missing HAM-D outcomes in SLAM DUNC did not induce an appreciable amount of 
selection bias in the clinical trial (Table 2). However, the mean of the IPOW weight was 1.06 
(mean 1.06-1.07 for un-truncated and all truncated weights, see Supplemental Digital 
Content Appendix Table 1), rather than 1.00, which may indicate a degree of 
misspecification of the weight model or non-positivity.35 When IPSW were used to 
standardize the effect of the intervention in SLAM DUNC to the target population in 
CNICS, the effect of the intervention was attenuated (mean decrease -2.4; 95% CI: -6.1, 
1.3). When both IPOW and IPSW were combined, the effect of the intervention was further 
attenuated (mean decrease -1.9; 95% CI: -5.3, 1.5). Similar trends were seen when Hispanics 
and other race/ethnicity, those not on ART and IDUs were excluded and when only CNICS 
sites in the Southeast United States were included (Table 2).
Discussion
In our analysis, the effect of MBC on depression at 6 months remained protective, but was 
attenuated when transported from the SLAM DUNC trial to a target population of depressed, 
HIV-infected adults in CNICS. In the trial, participants in the intervention arm experienced a 
3.6 point improvement on average in their depression on the HAM-D scale. When 
transported to CNICS, we estimated between a 1.9 and 2.4 point improvement in depression. 
Some clinicians consider a 3 point change on the HAM-D scale to be clinically significant,36 
suggesting the intervention may still be helpful if implemented in CNICS but have less of an 
impact on clinical depression than among trial participants. Similar results were seen when 
analyses excluded populations with limited data in SLAM DUNC (Hispanic/other ethnicity, 
IDU, and those not on ART at baseline).
One reason the intervention effect may have been attenuated was that the trial population 
reflected the HIV epidemic in the Southeast United States.37 Compared to CNICS, more 
black, non-Hispanics, women, and people who contracted HIV through heterosexual contact 
were included in the trial (Figure 2). However, the effect of the intervention was stronger 
only among black, non-Hispanics; being female or having heterosexual transmission did not 
modify the intervention effect (Figure 3). Further, when we restricted analyses to CNICS 
sites within the Southeast United States only, we observed similar attenuation in the effect of 
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MBC on depression. These results suggest that differences in demographic characteristics do 
not fully account for why the effect of MBC may be attenuated if implemented in CNICS.
SLAM DUNC also enrolled a larger proportion of older participants who had been in care 
longer and had more severe depression, compared with CNICS. The MBC intervention was 
more effective for adults> 50 years of age and less effective for adults 30-39 years of age. 
Stratified estimates also suggested that the effectiveness of the intervention increased the 
longer a participant had been in care (Figure 3). This may reflect the fact that participants 
newly entering care may be dealing with the grief of a recent HIV diagnosis, rather than an 
episode of clinical depression. It is possible that more participants in SLAM DUNC had 
clinical depression, and thus the MBC intervention was more effective for these individuals.
Interestingly, fewer participants in SLAM DUNC experienced panic or were high risk 
alcohol or drug users than in CNICS. With the exception of drug use, these differences 
persisted when trial participants were compared to CNICS participants only in the SE United 
States. While these differences may reflect actual discrepancies between trial and CNICS 
participants, it is likely that they also reflect a degree of misclassification since measurement 
of these variables was not identical between SLAM DUNC and CNICS (Table 1). These 
measures represent the investigators' best efforts to match the constructs measured in both 
studies. However, the more stringent specifications in SLAM DUNC likely contributed to 
the smaller proportion of participants in the trial with panic disorder, drug and alcohol use. 
More generally, differences in how factors were measured highlights the importance of 
having reasonably similar measures to transport effect estimates.
Transporting an effect estimate from a RCT population to a target population rests on several 
assumptions. First, the distribution of effect-measure modifiers must be similar between the 
two populations.38 IPSW reweight the trial population to account for differences in the 
distribution of effect-measure modifiers in the target population. This approach relies on the 
assumption that all effect-measure modifiers (and determinants of selection into the trial) 
have been correctly measured and modeled. In our analysis, we were able to measure a 
number of variables associated with selection into the trial that also modified the treatment 
effect. However, some important effect-measure modifiers may have been misclassified 
(discussed above), not measured (e.g. adherence to antidepressant medication), or not 
measured consistently in the two populations (e.g. anxiety).
A second assumption of transporting effect estimates is that there is no interference. 
Interference affects the transportability of results to the extent that intervening on one 
individual in a given population affects the intervention status of another individual in that 
population.38 For example, in populations where more people tell their friends about starting 
depression treatment, the intervention could appear more effective because more individuals 
seek depression screening. In the SLAM DUNC trial all clinics implemented routine 
depression screening.15 Therefore, all patients had an equal probability of having their 
depression diagnosed and we assume negligible interference when transporting our results to 
CNICS.
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Finally, the version of an intervention an individual receives may affect the transportability 
of results if multiple versions of the intervention are available. In our analysis, we assume 
that any variation in the way MBC is delivered did not affect the outcome of an individual. 
In considering scaling-up the MBC intervention to all CNICS sites, treatment-variation 
irrelevance seems reasonable, given that MBC is a well-defined intervention that has been 
implemented in multiple settings.39-41 However, these results are based on an implicit 
assumption that MBC could be implemented in the target population with the same fidelity 
as it was in SLAM DUNC.
If implemented among HIV-infected depressed adults in routine care, MBC may be less 
effective than in the SLAM DUNC trial but can still be expected to reduce depression. 
Attenuation of the intervention effect reflects the fact that the trial enrolled a larger 
proportion of individuals for whom the intervention was more effective. These results 
highlight the heterogeneity in the effect of depression interventions across groups. Further 
research is needed to identify groups most likely to benefit from the MBC intervention, and 
those that may need alternative or additional interventions (e.g. substance abuse treatment). 
Given the considerable burden of depression among HIV-infected adults, interventions to 
help HIV providers better diagnose and treat depression are urgently needed. Intervention 
which combine antidepressant treatment with counseling may prove move effective for 
PLWH. As such interventions are developed and tested in RCTs, examining the 
transportability of trial findings is essential to understand whether similar effects can be 
expected if interventions are scaled-up.
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Figure 1. 
Distribution of covariates in entire SLAM DUNC sample (n=304), to those with a 6-month 
HAM-D (n=190).
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Figure 2. 
Distribution of demographic, HIV-related and mental health covariates in SLAM DUNC 
versus CNICS.
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Figure 3. 
Stratum-specific estimates of the effect of the MBC intervention on depression scores at 6 
months.
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Table 1
Measurement of Variables Investigated to Construct IPSW in SLAM DUNC and CNICS
Variable SLAM DUNC Measure CNICS measure
Same measure
 Baseline PHQ-9a PHQ-9, continuous PHQ-9, continuous
 Gendera female; male female; male
 Race/ethnicitya
white, non-Hispanic; black, non-Hispanic; 
Hispanic or other
white, non-Hispanic; black, non-Hispanic; 
Hispanic or other
 Risk group for HIV acquisitiona
IDU; MSM, no IDU; heterosexual, no MSM or 
IDU; other
IDU; MSM, no IDU; heterosexual, no MSM or 
IDU; other
 Baseline CD4 counta lab value from medical record, continuous lab value from medical record, continuous
 Baseline viral load suppressiona lab value from medical record, <50 copies/mL lab value from medical record, <50 copies/mL
 Years in HIV care from medical record from medical record
 Baseline ART use and adherencea
If on ART (yes/no) any self-reported missed doses 
in the last week
If on ART (yes/no) any self-reported missed 
doses in the last week
Different measures
 Panic disordera current panic disorder on the MINI
endorsement of any of 5 core symptoms of panic 
disorder
 Drug use meets criteria for drug use or dependence on the MINI
any self-reported drug use in the past 3 months, 
excluding marijuana
 High risk alcohol use meets criteria for alcohol abuse or dependence on the MINI > 4 on the AUDIT for men and > 3 for women
Abbreviations: PHQ-9 = Patient health questionnare-9; IDU = intravenous drug user; MSM = men who have sex with men; MINI = Mini 
International Neuropsychiatric Interview; AUDIT = Alcohol Use Disorders Identification Test.
a
Included in IPSW.
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Table 2
The Effect of Measurement-Based Care on Hamilton Depression Rating Scale (HAM-D) 
Scores 6 months
Restricted to non-IDUs, those on ART 
and non-Hispanic/Other ethnicity
Restricted to CNICS sites in the 
Southeast United Statesa
Mean Change (95% CI) in 
HAM-D at 6 months
Mean Change (95% CI) in HAM-D at 6 
months
Mean Change (95% CI) in HAM-D 
at 6 months
Unweighted -3.6 (-5.9, -1.3) -3.2 (-5.6, -0.8) n/a
Weighted
 IPOW -3.6 (-6.0, -1.3) -3.4 (-5.9, -0.9) n/a
 IPSW -2.4 (-6.1, 1.3) -1.5 (-5.3, 2.3) -1.5 (-5.3, 2.3)
 Weights combined -1.9 (-5.3, 1.5) -1.6 (-4.0, 0.8) -1.4 (-4.5, 1.8)
Abbreviations: IDU= Intravenous drug users.
aUniversity of North Carolina, Chapel Hill and University of Alabama-Birmingham
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